Course Provider
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Linked Courses
2
Active Listings
0
Primary Formats
Self-paced, Hybrid
Programs linked directly to this provider in the Blossom course dataset.
By COMPASS Pathways
An overview of investigational psilocybin therapy and how it is being studied for mental health conditions. It explains the treatment process, including preparation, the dosing session, and integration.
No medicine self-experience listed
By COMPASS Pathways
The COMPASS Therapist Training Programme enhances therapeutic skills through theoretical learning, practical training, & continuous mentoring.